AbbVie & Eisai’s Humira (adalimumab) Receives Approval for Hidradenitis Suppurativa in Japan

Shots:

• The approval is based on Japanese P-III study results assessing Humira (adalimumab) in patients with moderate-to-severe HS, evaluating its efficacy and safety
• The study resulted in meeting its 1EPs as HiSCR @12 wks. in 13/15 patients, ADRs in 6/15
• Humira (adalimumab) is an anti-TNF-α mAb approved in Japan for rheumatoid arthritis (RA), plaque psoriasis, arthritic psoriasis, pustular psoriasis, ankylosing spondylitis

Click here to read full press release/ article | Ref: Eisai Co | Image: News Pharmaceutical